Pegylated liposomal doxorubicin-induced hand-foot syndrome predicted by serum metabolomic profiling and prevented by calcium dobesilate

To the Editor: Pegylated liposomal doxorubicin (PLD) has been routinely used to treat patients with various types of cancers, including breast and ovarian cancer. However, it frequently causes hand-foot syndrome (HFS), which always results in a requirement for dose reduction or even drug withdrawal in severe cases.1,2 Although some treatments, such as regional cooling, topical urea, antioxidants, and steroids, have the goal of symptom control, there are still no effective treatments.3 Our study objective was to explore the biomarkers that can be used to predict the severity of HFS and to seek effective treatment methods.